Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

Benzinga · 2d ago
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.